We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours (PhAST)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05495295
Recruitment Status : Recruiting
First Posted : August 10, 2022
Last Update Posted : August 10, 2022
Sponsor:
Information provided by (Responsible Party):
Phost'In Therapeutics

Brief Summary:
The PhAST Trial is an adaptive first-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours conceived and designed with the contribution of the Gianni Bonadonna Foundation, a non-profit academic research institution aimed at promoting therapeutic innovation in oncology.. The trial includes two parts, a dose escalation phase which will enroll patients with non-selected tumour types, followed by a cohort expansion phase in selected tumour types.

Condition or disease Intervention/treatment Phase
Malignant Tumor Advanced Solid Tumor Glioblastoma Multiforme Metastatic Cancer Drug: PhOx430 Phase 1

Show Show detailed description

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 146 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Intervention Model Description: First-in-human clinical trial, including two parts: a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types.
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Adaptive First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Patients With Advanced Solid Tumours (PhAST Trial)
Actual Study Start Date : July 18, 2022
Estimated Primary Completion Date : June 30, 2023
Estimated Study Completion Date : July 31, 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Advanced Solid Tumours

First-in-human clinical trial of the acetylglucosaminyltransferase V inhibitor PhOx430 in patients with advanced solid tumours. The trial includes two parts, a dose escalation phase (part I) which will enroll patients with non-selected tumour types, followed by a cohort expansion phase (part II) in selected tumour types:

  • Glioblastoma Multiforme (GBM)
  • Triple Negative Breast Cancer (TNBC)
  • Selected solid tumours
Drug: PhOx430

Dose Escalation Phase: A standard 3 + 3 design will be followed for the escalation phase. PhOx430 will be administered orally twice a day (bid), at a 12-hour interval, continuously in cycles of 21 days. At each dose level (DL), three patients will be included and the first patient will be observed for at least 21 days before enrolling the following two. Three additional patients will be enrolled at each DL if a DLT is observed in the first three patients.

A maximum of 4 increasing Dose Levels are foreseen (10, 20, 40 and 70 mg/kg/day), and PhOx430 will be administered in two doses at a 12-hour interval.





Primary Outcome Measures :
  1. DOSE ESCALATION PRIMARY OUTCOME (Dose Limiting Toxicities (DLTs) at cycle 1) [ Time Frame: At the end of Cycle 1 (each cycle is 21 days) ]
    Dose Limiting Toxicities (DLTs) at cycle 1

  2. DOSE EXPANSION PRIMARY OUTCOME (treatment-emergent Adverse Events) [ Time Frame: Through study completion, up to 5 years ]
    Incidence, severity and seriousness of treatment-emergent Adverse Events (AEs)


Secondary Outcome Measures :
  1. DOSE ESCALATION SECONDARY OUTCOME #1 (treatment-emergent Adverse Events) [ Time Frame: Through study completion, up to 5 years ]
    Incidence, severity and seriousness of treatment-emergent Adverse Events (AEs)

  2. DOSE ESCALATION SECONDARY OUTCOME #2 (Plasma concentration levels of PhOx430) [ Time Frame: During Cycle1 and Cycle 2 (each cycle is 21 days) ]
    Plasma concentration levels of PhOx430

  3. DOSE ESCALATION SECONDARY OUTCOME #3 (Objective response rate) [ Time Frame: Through dose escalation completion, an average of 1 year ]
    Objective response rate (ORR)

  4. DOSE EXPANSION SECONDARY OUTCOME #1 (Plasma concentration levels of PhOx430 ) [ Time Frame: During Cycle1 and Cycle 2 (each cycle is 21 days) ]
    Plasma concentration levels of PhOx430

  5. DOSE EXPANSION SECONDARY OUTCOME #2 (Objective response rate) [ Time Frame: Through dose expansion completion, an average of 1.5 year ]
    Objective response rate (ORR)

  6. DOSE ESCALATION SECONDARY OUTCOME #4 (progression-free survival) [ Time Frame: Through study completion, up to 5 years ]
    progression-free survival (PFS)

  7. DOSE ESCALATION SECONDARY OUTCOME #5 (overall survival) [ Time Frame: Through study completion, up to 5 years ]
    overall survival (OS)

  8. DOSE EXPANSION SECONDARY OUTCOME #3 (progression-free survival) [ Time Frame: Through study completion, up to 5 years ]
    progression-free survival (PFS)

  9. DOSE EXPANSION SECONDARY OUTCOME #4 ( overall survival) [ Time Frame: Through study completion, up to 5 years ]
    overall survival (OS)



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 80 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Histologically or cytologically confirmed diagnosis of cancer.

    1. Dose escalation phase: patients with any solid tumour type or histology.
    2. Expansion cohort 1: Patients affected by GBM.
    3. Expansion cohort 2: Patients with triple-negative breast cancer (TNBC), defined as estrogen receptor (ER) negative (< 1% of nuclei reacting for ER in IHC), progesterone receptor (PgR) negative (< 1% of nuclei reacting for PgR in IHC), HER2 negative (IHC score = 1 or FISH negative for HER2 overexpression).
    4. Expansion cohort 3: Patients affected by solid tumour types selected by the PSC, on the basis of preclinical pharmacological data and of the antitumour activity observed during the dose escalation phase if any.
  2. Radiologically documented progressive disease after at least one prior treatment for metastatic/advanced disease.
  3. Lack of standard effective treatment options.
  4. Female or male patients of ≥ 18 years and ≤ 80 years
  5. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. For GBM patients: Karnofsky Performance Status ≥ 50%.
  6. Recovery from acute reversible toxicities of previous treatment to Grade ≤ 1.
  7. Tumour tissue accessible for repeated biopsies (except GBM patients).
  8. For GBM patients: stable dose of corticosteroids for > 5 days before the baseline MRI scan.
  9. For non-GBM patients: Measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST) guideline V1.1 (specifically, no ascites, pleural or pericardial effusions, osteoblastic bone metastases, or carcinomatous lymphangitis of the lung as the only lesion). For GBM patients: Measurable disease as defined by RANO criteria.
  10. Adequate bone marrow function defined as:

    1. absolute neutrophil count ≥ 1.5 x 109/L (being > 2 weeks off hematopoietic growth factors),
    2. platelet count ≥ 100,000 x 109/L,
    3. hemoglobin ≥ 9 g/dl without transfusions in the last 2 weeks.
  11. Adequate hepatic function defined as:

    1. total bilirubin < 1.5 x the upper limit of normal (ULN),
    2. ALT /AST (SGPT/SGOT) < 3 x ULN (< 5 x ULN in the presence of known hepatic metastases),
  12. Adequate renal function defined as estimated glomerular filtration rate (eGFR) of > 50 ml/min/1.73 m2 according to the CKD-EPI formula.
  13. Adequate coagulation, defined as INR < 1.5 and aPTT < 1.5 × ULN. This applies only to patients who are not receiving therapeutic anticoagulation; patients receiving therapeutic anticoagulation should be on a stable dose.
  14. Written informed consent obtained prior to any trial-specific screening procedures.
  15. Life expectancy of at least 3 months
  16. Women of childbearing potential must have a negative serum pregnancy test obtained within 28 days prior to treatment start; in addition, the negative result is to be confirmed by a repeat urine or serum pregnancy test within 72 hours before study treatment start if the screening test was performed earlier.
  17. Female patients who are not postmenopausal ("postmenopausal" defined as ≥ 12 months of non-therapy-induced amenorrhea) or surgically sterile (absence of ovaries and/or uterus) must agree to practice a highly effective method of contraception throughout the study for at least 6 months after the last dose of study drug. Highly effective methods of contraception are those that alone or in combination result in a failure rate of a Pearl Index of < 1% per year when used consistently and correctly. Sexual abstinence is only acceptable if it is in line with the preferred and usual lifestyle of the patient. Periodic abstinence (e.g., calendar, ovulation, symptothermal, or postovulation methods) and withdrawal are not acceptable methods of contraception.
  18. Male patients must agree to remain sexually abstinent or use a condom during the treatment period and for at least 90 days after the last dose of study drug.
  19. Patients must be able to take IMP at home and to properly use the provided dosing device.

Exclusion Criteria:

  1. Major surgery, chemotherapy, radical radiotherapy, investigational agents, or other anticancer therapy in the last 4 weeks before treatment start.
  2. For all patients with the exception of GBM patients: active central nervous system (CNS) metastases, as indicated by clinical symptoms, cerebral edema, and/or progressive growth (subjects with a history of CNS metastases or cord compression are allowable if they have been definitively treated and have been clinically stable for at least 3 months, and off steroids or anticonvulsants, before day 1 treatment).
  3. For GBM patients: disease progression within three months following last prior radiation therapy.
  4. Inability or unwillingness to swallow.
  5. Any other cancer within 3 years prior to enrolment, with the exception of adequately treated carcinoma in situ of the cervix uteri, or adequately treated basal or squamous cell carcinoma of the skin.
  6. Significant liver disease, including active viral, alcoholic or other hepatitis and cirrhosis.
  7. History of HIV infection, active hepatitis B (chronic or acute), or hepatitis C infection. Patients with past or resolved hepatitis B infection (defined as having a negative HBsAg test and positivity for antibodies for hepatitis B core antigen [anti-HBc]) are eligible. Patients positive for hepatitis C virus (HCV) antibody are eligible only if PCR is negative for HCV RNA
  8. Severe infections within 4 weeks prior to enrolment.
  9. Patients with a history of central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant and precluding informed consent or adversely affecting compliance with study drug.
  10. Baseline left ventricular ejection fraction (LVEF) < 50% by echocardiography or multi-gated scintigraphic scan (MUGA)
  11. Other current severe, uncontrolled systemic disease
  12. Treatment with CYP3A4/5 inhibitors within 5 drug elimination half-lives before study treatment start and/or inability or unwillingness to avoid such medications during study treatment
  13. Known hypersensitivity to any study drug components
  14. Pregnant or lactating women

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05495295


Contacts
Layout table for location contacts
Contact: Karine Chorro, Mrs. +33 (0) 4 11 93 77 51 phast@phostin.com

Locations
Layout table for location information
Italy
IRCCS Ospedale San Raffaele Recruiting
Milano, Italy, 20132
Contact: Gianluca Del Conte, MD    00390226432643    delconte.gianluca@hsr.it   
Sponsors and Collaborators
Phost'In Therapeutics
Investigators
Layout table for investigator information
Study Director: Alain Herrera, MD Phost'In Therapeutics
Principal Investigator: Diego Tosi, MD Institut du Cancer de Montpellier
Layout table for additonal information
Responsible Party: Phost'In Therapeutics
ClinicalTrials.gov Identifier: NCT05495295    
Other Study ID Numbers: PHOX-CLI_001
2021-004170-55 ( EudraCT Number )
First Posted: August 10, 2022    Key Record Dates
Last Update Posted: August 10, 2022
Last Verified: August 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms
Glioblastoma
Astrocytoma
Glioma
Neoplasms, Neuroepithelial
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Neoplasms, Nerve Tissue